AMEX:TRXC

Stock Analysis Report

Executive Summary

TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery.

Snowflake

Fundamentals

Mediocre balance sheet with limited growth.


Similar Companies

Share Price & News

How has TransEnterix's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-30.3%

TRXC

1.2%

US Medical Equipment

1.0%

US Market


1 Year Return

-92.3%

TRXC

14.9%

US Medical Equipment

8.0%

US Market

Return vs Industry: TRXC underperformed the US Medical Equipment industry which returned 14.9% over the past year.

Return vs Market: TRXC underperformed the US Market which returned 8% over the past year.


Shareholder returns

TRXCIndustryMarket
7 Day-30.3%1.2%1.0%
30 Day-55.9%-2.7%-0.07%
90 Day-77.5%-1.7%-1.0%
1 Year-92.3%-92.3%15.8%14.9%10.4%8.0%
3 Year-80.0%-80.0%71.4%66.2%46.2%36.7%
5 Year-92.6%-92.6%124.3%99.7%64.3%46.2%

Price Volatility Vs. Market

How volatile is TransEnterix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is TransEnterix undervalued compared to its fair value and its price relative to the market?

0.51x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TRXC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TRXC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TRXC is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: TRXC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TRXC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TRXC is good value based on its PB Ratio (0.5x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is TransEnterix forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

3.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TRXC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TRXC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TRXC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TRXC's revenue (43.6% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: TRXC's revenue (43.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TRXC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has TransEnterix performed over the past 5 years?

-19.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: TRXC is unprofitable, and losses have increased over the past 5 years at a rate of -19.2% per year.

Accelerating Growth: Unable to compare TRXC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TRXC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: TRXC has a negative Return on Equity (-52.74%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: TRXC is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: TRXC is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is TransEnterix's financial position?


Financial Position Analysis

Short Term Liabilities: TRXC's short term assets ($69.3M) exceeds its short term liabilities ($22.5M)

Long Term Liabilities: TRXC's short term assets (69.3M) exceeds its long term liabilities (49.4M)


Debt to Equity History and Analysis

Debt Level: TRXC's debt to equity ratio (22.5%) is considered satisfactory

Reducing Debt: TRXC's debt to equity ratio has increased from 4.7% to 22.5% over the past 5 years.


Balance Sheet

Inventory Level: TRXC has a low level of unsold assets or inventory.

Debt Coverage by Assets: TRXC's debt is covered by short term assets (assets are 2.347090x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TRXC has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: TRXC has less than a year of cash runway if free cash flow continues to reduce at historical rates of -2.3% each year


Next Steps

Dividend

What is TransEnterix's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate TRXC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate TRXC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if TRXC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TRXC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TRXC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of TransEnterix's salary, the management and board of directors tenure and is there insider trading?

4.2yrs

Average management tenure


CEO

Todd Pope (54yo)

6.1yrs

Tenure

US$3,564,942

Compensation

Mr. Todd M. Pope has been the Chief Executive Officer and President of TransEnterix, Inc. (alternate name SafeStitch Medical, Inc.) since September 3, 2013. He was the president and chief executive officer ...


CEO Compensation Analysis

Compensation vs. Market: Todd's total compensation ($USD3.56M) is about average for companies of similar size in the US market ($USD509.77K).

Compensation vs Earnings: Todd's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

4.2yrs

Average Tenure

50yo

Average Age

Experienced Management: TRXC's management team is considered experienced (4.2 years average tenure).


Board Age and Tenure

6.8yrs

Average Tenure

64yo

Average Age

Experienced Board: TRXC's board of directors are considered experienced (6.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Joe Slattery (54yo)

    Executive VP & CFO

    • Tenure: 6yrs
    • Compensation: US$2.27m
  • Todd Pope (54yo)

    CEO, President & Director

    • Tenure: 6.1yrs
    • Compensation: US$3.56m
  • Joshua Weingard (46yo)

    Chief Legal Officer & Secretary

    • Tenure: 6.1yrs
  • Stephanie Fitts (53yo)

    Vice President of Clinical

    • Tenure: 1.4yrs
  • Mohan Nathan

    Vice President of Global Marketing

    • Tenure: 0yrs
  • Paul Ziegler

    Vice President of Sales

    • Tenure: 4.2yrs
  • Anthony Fernando (47yo)

    Chief Operating Officer

    • Tenure: 2.3yrs
    • Compensation: US$2.26m
  • Eric Smith (47yo)

    Chief Commercial Officer

    • Tenure: 1.2yrs
    • Compensation: US$2.49m

Board Members

  • Bill Starling (66yo)

    Independent Director

    • Tenure: 6.8yrs
    • Compensation: US$190.12k
  • Rick Pfenniger (64yo)

    Independent Director

    • Tenure: 14.8yrs
    • Compensation: US$197.12k
  • Paul LaViolette (61yo)

    Independent Chairman of the Board

    • Tenure: 6.1yrs
    • Compensation: US$275.76k
  • William Kelley (80yo)

    Independent Director

    • Tenure: 4.8yrs
    • Compensation: US$187.12k
  • Steve Eubanks

    Member of Advisory Board

    • Tenure: 0yrs
  • W. Melvin

    Member of Advisory Board

    • Tenure: 0yrs
  • Todd Pope (54yo)

    CEO, President & Director

    • Tenure: 6.1yrs
    • Compensation: US$3.56m
  • David Albala

    Member of Advisory Board

    • Tenure: 0yrs
  • Jose Martinez

    Member of Advisory Board

    • Tenure: 0yrs
  • Aurora Pryor

    Member of Advisory Board

    • Tenure: 0yrs

Company Information

TransEnterix, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: TransEnterix, Inc.
  • Ticker: TRXC
  • Exchange: AMEX
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$78.278m
  • Shares outstanding: 255.64m
  • Website: https://www.transenterix.com

Number of Employees


Location

  • TransEnterix, Inc.
  • 635 Davis Drive
  • Suite 300
  • Morrisville
  • North Carolina
  • 27560
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TRXCAMEX (NYSE MKT LLC)YesCommon StockUSUSDSep 2013
2TXDB (Deutsche Boerse AG)YesCommon StockDEEURSep 2013
0LG9LSE (London Stock Exchange)YesCommon StockGBUSDSep 2013

Biography

TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-po ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/22 00:05
End of Day Share Price2019/10/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.